The efficacy and safety of transcutaneous electrical nerve stimulation for labor analgesia in the first stage of labor: a qualitative and quantitative analysis

经皮神经电刺激镇痛在第一产程中的有效性和安全性:定性和定量分析

阅读:1

Abstract

AIM: Labor pain represents a significant challenge for parturients during childbirth. Transcutaneous electrical nerve stimulation (TENS) is an effective analgesic modality. However, its efficacy and safety for intrapartum analgesia remain unclear. To address this knowledge gap, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to comprehensively assess the analgesic effectiveness and safety profile of TENS during the first stage of labor. METHODS: We searched databases from inception to October 17, 2024 and updated them to July 22, 2025. Paired researchers independently extracted data and assessed the risk of bias. All meta-analyses were performed via random effects models, and the GRADE approach was employed to evaluate the certainty of evidence. RESULTS: We included 51 randomized controlled trials (10,038 participants, all females). Low evidence showed that compared with the blank control, parturients using TENS may experience more pain relief (WMD -1.98 cm, 95%CI -2.6 to -1.35 cm, the modelled RD 52, 95% CI 37 to 62%), parturients using TENS may shorten the duration of the first stage of labor (WMD -46.78 min,95% CI -61.32 to -32.25 min); compared with the epidural analgesia groups, parturients using TENS may shorten the duration of the first stage of labor (WMD-62.22 min, 95%CI -92.51 to -31.94 min). CONCLUSION: Compared with the blank control, TENS may reduce pain intensity and shorten the duration of the first stage of labor in parturients, with little to no difference in adverse events. When compared to epidural analgesia, TENS may shorten the duration of the first stage of labor, with very small differences observed in analgesic efficacy or adverse effects. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251066439, identifier PROSPERO (CRD420251066439).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。